[go: up one dir, main page]

CO6331462A2 - Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa - Google Patents

Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa

Info

Publication number
CO6331462A2
CO6331462A2 CO10109309A CO10109309A CO6331462A2 CO 6331462 A2 CO6331462 A2 CO 6331462A2 CO 10109309 A CO10109309 A CO 10109309A CO 10109309 A CO10109309 A CO 10109309A CO 6331462 A2 CO6331462 A2 CO 6331462A2
Authority
CO
Colombia
Prior art keywords
group
substituted
atom
alkyl group
compound
Prior art date
Application number
CO10109309A
Other languages
English (en)
Inventor
Akihiro Furukawa
Takehiro Fukuzaki
Yukari Onishi
Hideki Kobayashi
Takeshi Honda
Yumi Matsui
Masahiro Konoshi
Kenjiro Ueda
Tetsuyoshi Matsufuji
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6331462A2 publication Critical patent/CO6331462A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto que tiene una actividad activadora de gIucocinasa superior y está representado por la fórmula general (I), y las sales aceptables del mismo:en donde: A representa, por ejemplo, un átomo de oxigeno o un átomo de azufre, R1 representa, por ejemplo, un grupo alquilo de C1-C6, un grupo alcoxi de C1-C6 o un grupo alquilo de C1-C6 halogenado, A y R1 junto con el átomo de carbono al que están unidos, forman un grupo heterocíclico que puede estar sustituido con 1 a 3 grupos seleccionados independientemente del conjunto de sustituyentes a, R2 representa un grupo fenilo que puede estar sustituido con 1 a 5 grupos seleccionados independientemente del conjunto de sustituyentes a, o un grupo heterocíclico que puede estar sustituido con 1 a 3 grupos seleccionados del conjunto de sustituyentes a, R3 representa un grupo hidroxi o un grupo alcoxi de C1-C8, y el conjunto de sustituyentes a consiste, por ejemplo, en un átomo de halógeno, un grupo alquilo de C1-C6, un grupo alquilo C1-C6 sustituido con 1 o 2 grupos hidroxi; un grupo alquilsulfonilo de C1-C6 y un grupo representado por la fórmula -V-NR5R6 (en donde V representa un grupo carbonilo o un grupo sulfonilo, y R5 y R6 pueden ser iguales o diferentes entre sí y representan respectivamente un átomo de hidrógeno o un grupo alquilo de C1-C6, o R5 y R6, junto con el átomo de nitrógeno al que están unidos, forman un heterociclo saturado de 4 a 6 miembros que puede estar sustituido con 1 o 2 grupos seleccionados independientemente de un grupo alquilo de C1-C6 y un grupo hidroxi, y el heterociclo saturado de 4 a 6 miembros también puede contener un átomo de oxígeno o un átomo de nitrógeno.
CO10109309A 2008-02-06 2010-09-03 Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa CO6331462A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008026519 2008-02-06
JP2008314479 2008-12-10

Publications (1)

Publication Number Publication Date
CO6331462A2 true CO6331462A2 (es) 2011-10-20

Family

ID=40952154

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10109309A CO6331462A2 (es) 2008-02-06 2010-09-03 Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa

Country Status (20)

Country Link
US (2) US8017610B2 (es)
EP (1) EP2239253B1 (es)
JP (2) JP4503101B2 (es)
KR (1) KR20100118979A (es)
CN (1) CN102015637B (es)
AU (1) AU2009211718B2 (es)
BR (1) BRPI0908124A2 (es)
CA (1) CA2715143C (es)
CO (1) CO6331462A2 (es)
DK (1) DK2239253T3 (es)
ES (1) ES2425190T3 (es)
IL (1) IL207372A0 (es)
MX (1) MX2010008637A (es)
MY (1) MY150269A (es)
NZ (1) NZ587126A (es)
PL (1) PL2239253T3 (es)
PT (1) PT2239253E (es)
RU (1) RU2470917C2 (es)
TW (1) TWI432429B (es)
WO (1) WO2009099080A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082601A1 (ja) * 2009-01-16 2010-07-22 第一三共株式会社 新規２，５－二置換ピロール誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011122458A1 (ja) * 2010-03-29 2011-10-06 第一三共株式会社 含窒素芳香環化合物
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2703400A4 (en) * 2011-04-27 2014-10-08 Daiichi Sankyo Co Ltd PHENYLPYRROLDERIVAT CRYSTAL
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018019758A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
EP3275877A1 (en) 2016-07-28 2018-01-31 Basf Se Herbicidal pyridine compounds
WO2018019770A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyridine compounds
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN112707898A (zh) * 2020-12-21 2021-04-27 徐新杰 一种杂芳基取代的吡嗪衍生物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
PT1169312E (pt) 1999-03-29 2005-01-31 Hoffmann La Roche Activadores de glicocinase
WO2003080585A1 (en) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
RU2329261C2 (ru) * 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. Новое 2-гетероарил-замещенное производное бензимидазола
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
RU2392275C2 (ru) 2004-02-18 2010-06-20 Астразенека Аб Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
GB0403593D0 (en) * 2004-02-18 2004-03-24 Astrazeneca Ab Compounds
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
WO2005108393A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2006132436A1 (ja) * 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
KR100965040B1 (ko) 2005-07-11 2010-06-21 미쓰비시 타나베 파마 코퍼레이션 옥심 유도체 및 그의 제조 방법
JP2009508832A (ja) 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ グルコキナーゼ活性化剤としてのヘテロ二環式化合物
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
EP1960386A2 (en) 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
JP2009518286A (ja) 2005-11-01 2009-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしてのジヒドロイソインドロン
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
CA2647208C (en) 2006-03-24 2014-05-13 Array Biopharma Inc. Glucokinase activators
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound

Also Published As

Publication number Publication date
TW200938539A (en) 2009-09-16
KR20100118979A (ko) 2010-11-08
JP5074545B2 (ja) 2012-11-14
AU2009211718A1 (en) 2009-08-13
JP4503101B2 (ja) 2010-07-14
CA2715143C (en) 2013-04-02
IL207372A0 (en) 2010-12-30
US8415359B2 (en) 2013-04-09
TWI432429B (zh) 2014-04-01
RU2010136953A (ru) 2012-03-20
NZ587126A (en) 2011-12-22
US8017610B2 (en) 2011-09-13
PL2239253T3 (pl) 2013-11-29
CN102015637B (zh) 2014-05-21
US20120022075A1 (en) 2012-01-26
PT2239253E (pt) 2013-09-17
WO2009099080A1 (ja) 2009-08-13
JP2010163449A (ja) 2010-07-29
MX2010008637A (es) 2010-08-30
DK2239253T3 (da) 2013-09-23
BRPI0908124A2 (pt) 2015-08-04
CA2715143A1 (en) 2009-08-13
EP2239253B1 (en) 2013-06-19
EP2239253A4 (en) 2011-02-23
AU2009211718B2 (en) 2011-08-11
HK1148740A1 (en) 2011-09-16
JPWO2009099080A1 (ja) 2011-05-26
EP2239253A1 (en) 2010-10-13
MY150269A (en) 2013-12-31
ES2425190T3 (es) 2013-10-14
CN102015637A (zh) 2011-04-13
RU2470917C2 (ru) 2012-12-27
US20110003787A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR117916A1 (es) Compuesto heterocíclico y su uso
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
ECSP088150A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR049446A1 (es) Preparacion de pregabalina ((s)-(+)-aminometil-5-metilhexanoico) y compuestos relacionados
MY169179A (en) Novel piperidine compound or salt thereof
EA201170096A1 (ru) Замещенные производные пиримидона
AR044795A1 (es) Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv
AR055144A1 (es) Inhibidor de secrecion acida
CO6160266A2 (es) Derivado de oxopirazina y herbicida
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR111682A1 (es) Derivados de imidazopirimidina con sustituyentes fenilo y piridilo que contienen azufre
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
AR066605A1 (es) Derivados de heteroarilamida pirimidona
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии

Legal Events

Date Code Title Description
FG Application granted